Key result
A novel non-cell-based assay for detecting neutralizing antibodies to interferon-beta showed good correlation with existing cell-based assays, despite having lower sensitivity.
Population
Clinical samples from multiple sclerosis patients treated with interferon-beta
Comparison
Non-cell-based neutralizing antibody assay… vs Existing cell-based NAb assays
Design
Other
Authors
Loading...
May offer a simpler alternative for immunogenicity testing; leaves open prospective validation of clinical utility.
A non-cell-based assay for detecting neutralizing antibodies to interferon-beta showed good correlation with traditional cell-based assays, offering a practical alternative for immunogenicity assessment despite lower sensitivity.
Cludts et al. (2013) studied Multiple sclerosis. Non-cell-based NAb assay vs. Cell-based NAb assays was evaluated on Neutralizing antibody (NAb) titers and assay sensitivity/correlation. A novel non-cell-based assay for detecting neutralizing antibodies to interferon-beta showed good correlation with existing cell-based assays, despite having lower sensitivity.
Synapse has enriched 3 closely related papers on similar clinical questions. Consider them for comparative context: